SCHEMBL19486470

SCHEMBL19486470

CCN1CC2(C1)CN(c1ccc(-c3cc4c(N5CCN(C=O)CC5)ccnn4c3)cc1)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 3/20 0.36
USP2 O75604 6/20 0.35
SMN1; SMN2 Q16637 5/20 0.35
HSD17B10 Q99714 5/20 0.35
CYP2C19 P33261 3/20 0.35
CYP2C9 P11712 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP3A4 P08684 4/20 0.34
MAPK1 P28482 2/20 0.34
HIF1A Q16665 2/20 0.34
MAP4K4 O95819 2/20 0.34
ALDH1A1 P00352 3/20 0.34
HPGD P15428 2/20 0.34
CYP1A2 P05177 3/20 0.33
ACHE P22303 1/20 0.33
CHRNA7 P36544 1/20 0.33
RET P07949 2/20 0.33
TMEM97 Q5BJF2 1/20 0.32
USP8 P40818 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19486329 0.89 CHRNA7 (0.44) KITUSP2SMN1; SMN2MAP4K4ACHE
SCHEMBL19486485 0.87 KIT (0.36) KITUSP2SMN1; SMN2HSD17B10CYP2C19
SCHEMBL19486466 0.83 HSD17B10 (0.41) KITUSP2SMN1; SMN2HSD17B10CYP2C19
SCHEMBL19481780 0.83 ALDH1A1 (0.39) USP2SMN1; SMN2HSD17B10KMT2AMAPK1
SCHEMBL19481875 0.81 RET (0.35) KITUSP2SMN1; SMN2HSD17B10CYP2C19
SCHEMBL19481871 0.81 RET (0.35) KITUSP2SMN1; SMN2HSD17B10CYP2C19
SCHEMBL19481943 0.81 RET (0.36) USP2SMN1; SMN2HSD17B10CYP2C19CYP3A4
SCHEMBL19486749 0.80 KIT (0.36) KIT
SCHEMBL19486352 0.80 KIT (0.39) KITMAP4K4ALDH1A1USP8
SCHEMBL19486377 0.80 KIT (0.36) KITRET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11634422-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2023-04-25 US disclosed
US-10233186-B2 Inhibitors of activin receptor-like kinase BLUEPRINT MEDICINES CORPORATION (US) 2019-03-19 US disclosed
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE BLUEPRINT MEDICINES CORPORATION 2017-10-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634422-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 KIT 189/4885USP2 1649/4885SMN1; SMN2 3856/4885
US-10233186-B2 Inhibitors of activin receptor-like kinase ACVR1, ACVR2A, ACVRL1 KIT 27/4885USP2 2639/4885SMN1; SMN2 3350/4885
US-20170298069-A1 INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE ACVR1, ACVR2A, ACVRL1 KIT 189/4885USP2 1649/4885SMN1; SMN2 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.